Phaseline

Targets › GCG

GCG (Pro-glucagon [Cleaved into: Glicentin; Glicentin-related polypeptide): drug programs, companies and trials

2 programs from 2 companies in 23 trials: 12 Phase 1, 10 Phase 3, 1 Phase 2; Metabolic and endocrine, Oncology, Cardiovascular; next expected readout Jan 2027.

[Glucagon]: Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. (UniProt, P01275)

Open in Phaseline: the race on GCG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Novo NordiskCagrilintide B
Dual GLP-1/glucagon receptor agonist
GLP1R, GCG, CALCRPhase 3Obesity; Overweight; Cardiovascular Disease; Diabetes Mellitus, Type 2Jan 2027
AstraZenecaAZD6234 in combination with AZD9550
Dual GCG and GLP-1 receptor agonist
GCG, GLP1RPhase 2Obesity/Overweight; Healthy Participants; Overweight and Obesity; Hepatic ImpairmentJan 2027

Conditions

Obesity (11) Overweight (5) Healthy Participants (2) Obesity/Overweight (1) Overweight and Obesity (1) Hepatic Impairment (1) Cardiovascular Disease (1) Diabetes Mellitus, Type 2 (1)

Modalities

small molecule (1), protein or peptide (1)

Companies

AstraZeneca (1) Novo Nordisk (1)

Related targets

GLP1R (2) CALCR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.